Related references
Note: Only part of the references are listed.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nisha B. Nagarsheth et al.
NATURE MEDICINE (2021)
αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib
Juemin Fang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Vulval squamous cell carcinoma and its precursors
Naveena Singh et al.
HISTOPATHOLOGY (2020)
CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies
Alba Rodriguez-Garcia et al.
MOLECULAR THERAPY (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Killing cervical cancer cells by specific chimeric antigen receptor-modified T cells
Yue He et al.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer
Yan Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Manufacturing chimeric antigen receptor T cells: issues and challenges
Claire Roddie et al.
CYTOTHERAPY (2019)
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
Andrew R. Haas et al.
MOLECULAR THERAPY (2019)
1183PDAdoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours
M O Butler et al.
ANNALS OF ONCOLOGY (2019)
1227PHPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer
P Bryson et al.
ANNALS OF ONCOLOGY (2019)
Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities
Xiaotao Jiang et al.
CANCER LETTERS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
Y. Lai et al.
LEUKEMIA (2018)
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
Franziska Blaeschke et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities
Alia Ghoneum et al.
CANCER MEDICINE (2018)
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Benjamin Y. Jin et al.
JCI INSIGHT (2018)
The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate
Kristin L. M. Boylan et al.
ONCOTARGET (2017)
Human memory CD8 T cell effector potential is epigenetically preserved during in vivo homeostasis
Hossam A. Abdelsamed et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms
Danilo Presotto et al.
FRONTIERS IN IMMUNOLOGY (2017)
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
Congcong Zhang et al.
FRONTIERS IN IMMUNOLOGY (2017)
CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
Vita Golubovskaya et al.
CANCERS (2017)
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System
Drew C. Deniger et al.
MOLECULAR THERAPY (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette et al.
BLOOD (2013)
Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells
Brian J. Cameron et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
Antonio Di Stasi et al.
BLOOD (2009)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
RJ Brentjens et al.
NATURE MEDICINE (2003)
Share Paper
